- Alzamend Neuro Inc ALZN has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application.
- Today's response provides a path for its planned clinical development of AL002, the Company says.
- AL002 uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
- The FDA agreed to Alzamend's proposed combined Phase 1/2 study.
- Alzamend will file the IND by the end of November and initiate the clinical trial of AL002 in Q1 of 2022.
- Related: Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate.
- Price Action: ALZN stock increased 33.5% at $3.04 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralAlzheimer's diseaseBriefsPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
